|
KMID : 1151620160010020079
|
|
Journal of Retina
2016 Volume.1 No. 2 p.79 ~ p.84
|
|
|
Safety of Intravitreal Anti-vascular Endothelial Growth Factor in Patients with Cardiovascular or Cerebrovascular Disorders
|
|
Han Sang-Youn
Kim Jae-Hui
Kim Jong-Woo
Kim Chul-Gu
Lee Dong-Won
Yoo Su-Jin
|
|
|
Abstract
|
|
|
Purpose: To evaluate the safety of intravitreal anti-vascular endothelial growth factor (VEGF) injection for exudative age-related macular degeneration (AMD) in patients diagnosed with cardiovascular or cerebrovascular disorder.
Methods: Retrospective review of medical records was performed for 37 patients diagnosed with angina, myocardial infarction, or cerebral infarction and who received intravitreal anti-VEGF injection to treat exudative AMD. Patients who were followed-up for 6 months or longer were included. Aggravation or development of the disorder was verified.
Results: Thirty, 3, and 8 patients were diagnosed to have angina, myocardial infarction, and cerebral infarction, respectively. A mean of 4.8 ± 2.8 intravitreal anti-VEGF injections were administered during the study period. The mean follow-up period between the first injection and the last follow-up was 17.6 ± 8.8 months. Aggravation of angina was reported in one patient (2.7%), and the patient underwent coronary artery stent insertion 6 months after initial anti-VEGF treatment.
Conclusions: In the present study, we could not found any evidence that anti-VEGF therapy is associated with progression of cardiovascular or cerebrovascular disorders. Further studies with a larger study population are needed to confirm our findings.
|
|
|
KEYWORD
|
|
|
Anti-vascular endothelial growth factor, Cardiovascular, Cerebrovascular, Exudative age-related macular degeneration, Safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|